Start-Up Previews (12/2010)
Executive Summary
A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.
You may also be interested in...
ZetrOZ LLC
Traditional home treatments for chronic pain, such as topical creams, hot pads, cold packs, prescription drugs and transcutaneous nerve stimulation are plentiful, yet only half of America's chronic pain sufferers report their pain as under control. Consumers may soon have a better option for treating their pain: a wearable ultrasound system that is portable, affordable and easy to use. TheraSonX from ZetrOZ LLC uses low-intensity ultrasound delivered through an iPod-sized applicator to provide continuous therapy for up to six hours while patients are engaged in normal activities.
Zeltiq
Zeltiq was founded to commercialize technology based on research demonstrating that fat cells are more susceptible than other types of cells to extreme cold and can be selectively, painlessly and permanently destroyed in a process known as cryolipolysis. With FDA 510(k) clearance for its CoolSculpting system in hand in early September, Zeltiq hopes to lead the charge into the body contouring aesthetics frontier with a technology that it believes stands apart from emerging laser, radiofrequency and ultrasound systems.
NuVue Therapeutics Inc.
A game-changing, silver-bullet approach for diagnosing and treating soft-tissue cancers could replace traditional biopsy techniques and IV chemotherapy. Or so hopes NuVue Therapeutics Inc., which is developing a suite of products that could allow more precise tissue removal through an ultrasound-guided needle with color monitoring for easy visibility, plus reduce the current high rates of toxicity and morbidity associated with chemotherapy. The company says its technology enables very low-volume/highly concentrated dosing, just 1/200th to 1/500th of the standard dose of systemic chemotherapy.